Brief: Hansoh Pharmaceutical Says NDA For Olatorepatide Injection Accepted By China's NMPA
04/06/2026 24:49
BRIEF-Hansoh Pharmaceutical Says NDA For Olatorepatide Injection Accepted By China's NMPA June 4 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK:
NDA FOR OLATOREPATIDE INJECTION ACCEPTED BY NMPA OF CHINA FOR CHRONIC WEIGHT MANAGEMENT
Further company coverage: 3692.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsFactbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Hansoh Pharmaceutical Says NDA For Olatorepatide Injection Accepted By China's NMPA
J&T Global Express leads gain in newcomers to Hang Seng Index